



## **Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGNificant Options in Healthcare Conference**

February 28, 2008

SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that Charles Butler, the company's senior director of investor relations, will present at the Susquehanna SIGNificant Options in Healthcare Conference at 10:00 a.m. ET / 7:00 a.m. PT on Tuesday, March 4, 2008.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at <http://www.exelixis.com>.

### About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

SOURCE Exelixis, Inc.

CONTACT: investors, Charles Butler, Senior Director, +1-650-837-7277, [cbutler@exelixis.com](mailto:cbutler@exelixis.com), or media, Soleil Maxwell Harrison, Senior Manager, +1-650-837-7012, [sharrison@exelixis.com](mailto:sharrison@exelixis.com), both of Exelixis, Inc. Corporate Communications

Web site: <http://www.exelixis.com>